Join industry executives in staying informed on the market access and HTA process in Switzerland.  1. Please describe the main cost containment policies in place in your country and their fundamental principles: a. Pricing and impact of generic/biosimilar approval Based on a price comparison with 15 reference countries (containing among others, all of the 9…

Join industry executives in staying informed on the market access and HTA process in Denmark.    1. Please describe the main cost containment policies in place in your country and their fundamental principles  On an overall level, control of healthcare expenditures is based on budget laws and annual agreements between the Danish state, the regions…

Join industry executives in staying informed on the market access and HTA process in Romania.  1. Please describe the main cost containment policies in place in your country and their fundamental principles  a. Pricing and impact of generic/biosimilar approval The price of off-patent innovative medicines cannot exceed, as a rule: the level of the innovative…

1. Please describe the main cost containment policies in place in your country and their fundamental principles   a. Pricing and impact of generic/biosimilar approval Currently there are no policies in place in this regard.   b. Clawback/Payback/Discounts/Rebates In Portugal, the main mechanism for cost-containment is the prior evaluation, regulated by Decree-Law No. 97/2015 of…

Join industry executives in staying informed on the market access and HTA process in Brazil.  1. Please describe the main cost containment policies in place in your country and their fundamental principles a. Pricing and impact of generic/biosimilar approval Generic drugs must have their PF 35% cheaper than the corresponding reference drug, as mentioned in…

1. Please describe the main cost containment policies in place in your country and their fundamental principles: a. Pricing and impact of generic/biosimilar approval The entry of generics/biosimilars into the market affects the price of original drugs by three main mechanisms: (i) homogeneous groups (“HG”), (ii) reference groups (“RG”), (iii) market pressure. Products subject to…